novo nordisk glp-1 receptor agonist medications Novo's Wegovy becomes first drug approved for MASH Novo Nordisk's weight-loss pill wins
Description
Reference: Lhteenvuo M, Tiihonen J, Solismaa A, Tanskanen A, Mittendorfer-Rutz E, Taipale H
B., Reback C
doi: 10.1016/j.ejphar.2012.11.057
Sources: American Society for Metabolic and Bariatric Surgery (ASMBS), 2024 Annual Meeting NYU Langone Health Bariatric Surgery Research TODAY Health GLP-1 Drugs vs
Vilsbll T, Agers H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, et al
